The DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index; 19 of the 41 sources its claims cite were checked for support.
PU.1 dictates β-amyloid-induced TREM2 expression upregulation in microglia in a transgenic model of Alzheimer’s disease
Open accessAbstract
Microglial dysfunction is characteristic of Alzheimer’s disease (AD), with triggering receptor expressed on myeloid cells 2 (TREM2) and transcription factor PU.1 playing crucial roles. However, the relationship between TREM2 and PU.1 remains unclear. We investigated TREM2 and PU.1 expression patterns in the 5×FAD mouse AD model. Experimental approaches included quantitative qPCR, western blotting, immunofluorescence staining, chromatin immunoprecipitation, and luciferase reporter assays to examine the interaction between PU.1 and TREM2. The phagocytic function of microglial cells was evaluated using Aβ42 and Nile red fluorescent microsphere phagocytosis assays. TREM2 and PU.1 expression significantly correlated with brain β-amyloid (β) deposition. PU.1 directly interacted with the TREM2 promoter region, promoting its transcription and potently impacting microglial phagocytosis. PU.1 overexpression amplified TREM2 expression, while PU.1 knockdown reduced it. Our findings reveal a novel regulatory mechanism where PU.1 directly modulates TREM2 transcription in activated microglia during AD progression.
Overview
CoChat Summary
## TL;DR
In 5×FAD Alzheimer’s mice and microglia models, the paper argues that PU.1/Spi1 drives β-amyloid-induced TREM2 upregulation by binding TREM2 regulatory regions and boosting transcription. This PU.1–TREM2 axis was linked to microglial phagocytosis, with knockdown of either gene reducing uptake of Aβ/fibrillar particles.
## Key findings
- In 5×FAD mice, both TREM2 and PU.1 mRNA/protein levels were higher than in age-matched wild-type mice, and both increased with age; TREM2 showed no notable mRNA difference at 1 month of age, but was markedly elevated in aged mice (≥11 months).
- Double immunofluorescence showed nearly all TREM2-positive microglia were PU.1-positive and vice versa, and Pearson analysis found a robust positive correlation between TREM2 and PU.1 in 5×FAD mice.
- In BV2 microglia and primary microglia, oligomeric and fibrillar Aβ increased TREM2 expression in a time-dependent manner, with TREM2 becoming significant at 24 h after stimulation; PU.1 also rose, peaking at 12 h.
- PU.1 knockdown reduced TREM2 mRNA/protein, PU.1 overexpression increased TREM2, and ChIP-qPCR plus luciferase assays supported direct binding/activation of the TREM2 promoter; one assay showed about a 5-fold increase in luciferase activity with PU.1 coexpression.
- Functionally, TREM2 shRNA and PU.1 shRNA reduced Aβ42 uptake by approximately 55% and 50%, and reduced Nile red microsphere phagocytosis efficiency by approximately 33% and 30%, respectively.
## Methods
- Used male 5×FAD APP/PS1 double transgenic mice and age-matched wild-type controls; analyzed hippocampal/brain tissues and isolated primary microglia, alongside BV2 mouse microglial cells.
- Measured gene/protein expression and localization with qRT-PCR, western blotting, immunohistochemistry, and immunofluorescence; tested PU.1–TREM2 interaction with ChIP-qPCR and luciferase reporter assays.
- Assessed function with Aβ42 and Nile red fluorescent microsphere phagocytosis assays; statistics used one-way or two-way ANOVA with Bonferroni correction and Pearson correlation.
## Limitations
- The paper states it did not examine other transcription factors that may contribute to Aβ-mediated TREM2 expression.
- The authors note that siRNA/shRNA knockdown does not equal complete PU.1 genetic deletion, and they say a floxed PU.1 mouse model and conditional knockout studies would be better for in vivo validation.
- The paper says it relied heavily on BV2 cells for mechanistic work; it also notes BV2 cells do not fully recapitulate primary microglial gene expression/epigenetic features, and that future in vivo studies are needed.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
13 Valid · 3 Not valid · 13 Not checked · 76 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The Chip-seq results revealed 5,264 target genes for the PU.1 protein, including TREM2 (Satoh et al., 2014), suggesting that TREM2 is a possible target gene of PU.1.”
§ PU.1 dictates β-amyloid-induced TREM2 expression upregulation in microglia in a transgenic model of Alzheimer’s disease > 3 Results > 3.5 PU.1 facilitates TREM2 mRNA and protein expression
What the sources say
- Supportedcites Satoh et al., 2014 source
The Results section identifies 5,264 ChIP-Seq-based Spi1 target genes in mouse microglia and explicitly lists Trem2 among them. The Discussion likewise identifies Trem2 as a Spi1 target; the source states the citing sentence’s tentative conclusion with at least as much confidence. (LLM, conf=0.95)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Consistent with the findings of previous studies, we observed no change in TREM2 and PU.1 expression between 5 × FAD and WT mice at 1 month of age, a stage that precedes significant intraneuronal Aβ42 accumulation (Jay et al., 2015; Oakley et al., 2006).”
§ PU.1 dictates β-amyloid-induced TREM2 expression upregulation in microglia in a transgenic model of Alzheimer’s disease > 4 Discussion
What the sources say
- Could not verifycites Jay et al., 2015 sourceExperimental — accuracy not yet measured
The Figure 1 caption in Results and Discussion lists TREM2 measurements in 5XFAD mice beginning at 2 months, not 1 month. Searches for 1-month 5XFAD comparisons and PU.1 expression found no passage in our copy establishing that either marker was unchanged relative to WT at 1 month. (LLM, conf=0.76)
- Partly supportedcites Oakley et al., 2006 sourceExperimental — accuracy not yet measured
The section “Intraneuronal Aβ, neurodegeneration, and amyloid plaque formation” says intraneuronal Aβ is evident in the Tg6799 5xFAD line at 1.5 months, supporting the description of 1 month as an earlier stage. The paper does not report a 1-month comparison of TREM2 or PU.1 expression between 5xFAD and wild-type mice, so it cannot substantiate the quoted expression finding. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“In comparison, immortalized BV2 cells—despite expressing PU.1—lack key characteristics of primary microglia, such as the capacity to replicate the heterogeneity and functional diversity observed in vivo (He et al., 2018; Pimenova et al., 2021).”
§ PU.1 dictates β-amyloid-induced TREM2 expression upregulation in microglia in a transgenic model of Alzheimer’s disease > 4 Discussion
What the sources say
- Not matchedcites He et al., 2018
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Could not verifycites Pimenova et al., 2021 sourceExperimental — accuracy not yet measured
The Methods identify BV2 as a mouse microglial cell line, and the Discussion describes experiments using it to study PU.1. Neither passage compares BV2 cells with primary microglia or addresses whether they reproduce the heterogeneity and functional diversity seen in vivo; searches for those terms and for BV2 model limitations found no such passage. Page numbers were not available in our copy. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our investigation of PU.1 expression within the hippocampus of 5 × FAD mice revealed significant increases in the protein and mRNA levels of PU.1.”
- Also stated in: § 3.2 PU.1 expression is markedly increased in the hippocampus of 5 × FAD mice · boosted
“Western blotting and quantitative PCR assays corroborated these findings, showing that both the protein and mRNA expression levels of PU.1 were markedly elevated in the 5 × FAD mice compared with those in the age-matched wild-type controls.”
§ PU.1 dictates β-amyloid-induced TREM2 expression upregulation in microglia in a transgenic model of Alzheimer’s disease > 3 Results > 3.2 PU.1 expression is markedly increased in the hippocampus of 5 × FAD mice
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 3.2 PU.1 expression is markedly increased in the hippocampus of 5 × FAD mice · boosted
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“which also clustered around amyloid plaques”
§ PU.1 dictates β-amyloid-induced TREM2 expression upregulation in microglia in a transgenic model of Alzheimer’s disease > 3 Results > 3.1 TREM2 expression levels are significantly elevated in activated microglia
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
54 more claims
Create a free account to see all 105 claims and to verify the 5 references still open.
- Probably not a substantial claim. 22
- It may state two separate claims as one. 30
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“More recent Alzheimer’s-focused work has suggested that PU.1 can directly influence TREM2 expression during amyloid-β-induced microglial activation [35].”
From Lymphoid-like Suppressive Microglia in Alzheimer’s Disease: A New Neuroimmune Regulatory Axis? (2026) · cites this paper as [35]
Citations
Cites
Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530
TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., Young, K. L., Robinette, M. L., Gilfillan, S., Krishnan, G. M., Sudhakar, S., Zinselmeyer, B. H., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.049 · Cited by 1,736
Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways
Kierdorf, K., Erny, D., Goldmann, T., Sander, V., Schulz, C., Perdiguero, E. G., Wieghofer, P., Heinrich, A., Riemke, P., Hölscher, C., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3318 · Cited by 1,457
Bouchon, A., Dietrich, J., & Colonna, M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.4991 · Cited by 1,284
TREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease
Ulland, T. K., Song, W. M., Huang, S. C.-C., Ulrich, J. D., Sergushichev, A., Beatty, W. L., Loboda, A. A., Zhou, Y., Cairns, N. J., Kambal, A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.023 · Cited by 1,263
APOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches
Serrano-Pozo, A., Das, S., & Hyman, B. T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30412-9 · Cited by 1,037
TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge
Nugent, A. A., Lin, K., van Lengerich, B., Lianoglou, S., Przybyla, L., Davis, S. S., Llapashtica, C., Wang, J., Kim, D. J., Xia, D., et al. (2020) · Neuron · doi:10.1016/j.neuron.2019.12.007 · Cited by 798
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756 · cited 1×
“These genes include CLU, CR1 , CD33 , EPHA1 , and TREM2 , which are involved in immunity, and APOE and ABCA7 , which are involved in lipid processing (Kim et al., 2023; Raulin et al., 2022; Zhao et al., 2015).”
New insights into atypical Alzheimer's disease in the era of biomarkers
Graff-Radford, J., Yong, K. X. X., Apostolova, L. G., Bouwman, F. H., Carrillo, M., Dickerson, B. C., Rabinovici, G. D., Schott, J. M., Jones, D. T., & Murray, M. E. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30440-3 · Cited by 706
Cited by
Boreland, A. J., Abbo, Y., Li, X., Stillitano, A. C., Zhang, S., Duan, J., Pang, Z. P., & Hart, R. P. (2025) · Alcohol · doi:10.1016/j.alcohol.2025.10.006 · Cited by 10
Transcriptional Activation of the TREM2 Gene by ZEB2 in a Zinc Finger-Dependent Manner
Yanaizu, M., Takata, Y., Kato, M., Fujiwara, H., & Kino, Y. (2025) · Genes · doi:10.3390/genes16111329 · Cited by 1
Gui, S.-J., Gao, X., Zhang, P., Yong-hong, T., & Gao, J.-H. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02857-5
Li, Z., Ming, Q., Fu, L., Yang, J., Lv, Y., Chen, B., & Lu, Z. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1886340 · Cited by 1
Cui, X., Wei, Z., Wang, Q., Du, S., Lin, Z., Chen, Z., Zhang, J., Li, C., Tang, L., Dai, X., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1830927 · Cited by 1
“Similarly, our data showed that global microglial activation is hallmark in 5×FAD mice (Wei et al., 2025).”
Self-citation
Metadata
- Authors
- Wei, Z., Pan, X., Cui, X., Zhang, J., Dai, X., Zeng, Y., & Chen, X.
- Affiliations
- Fujian Medical University (CN)
- Fujian University of Traditional Chinese Medicine (CN)
- Corresponding author
- Pan, Xiaodong
- Chen, Xiaochun
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2025-05-01
- Volume
- 17
- Pages
- 1537388-1537388
- ISSN
- 1663-4365 (ISSN-L)
- PMC
- PMC12078285
- OpenAlex
- W4410014389
- Cited by
- 7
- References
- 69
- Citations by year
- 2026: 5 · 2025: 2
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Aging Neuroscience (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
- Keywords
- PU.1, TREM2, microglia, Alzheimer's disease, amyloid-beta, 5xFAD mice, microglial phagocytosis, microglial dysfunction, transcriptional regulation, therapeutic target
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PU.1 dictates β-amyloid-induced TREM2 expression upregulation in microglia in a transgenic model of Alzheimer’s disease. https://app.cochat.ai/papers/10.3389/fnagi.2025.1537388
- The paper
- Wei, Z., Pan, X., Cui, X., Zhang, J., Dai, X., Zeng, Y., & Chen, X. (2025). PU.1 dictates β-amyloid-induced TREM2 expression upregulation in microglia in a transgenic model of Alzheimer’s disease. Frontiers in Aging Neuroscience. https://doi.org/10.3389/fnagi.2025.1537388
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.